CORRECTION Open Access

Correction to: Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia



Juanjuan Zhao¹, Yongping Song^{1*} and Delong Liu^{1,2*}

Correction to: Biomark Res (2019) 7:19 https://doi.org/10.1186/s40364-019-0170-2

The original article [1] contains an error in the legend of Fig. 1 whereby it is incorrectly stated that MEC stands for 'mitoxantrone, etoposide, cyclophosphamide'.

It should instead be stated that MEC stands for 'mitoxantrone, etoposide, cytarabine'.

Author details


¹Department of Oncology, The first Affiliated Hospital of Zhengzhou University, Zhengzhou, China. ²Division of Hematology and Oncology, New York Medical College, Valhalla, USA.

Published online: 17 October 2019

Reference

 Zhao J, Song Y, Liu D. Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia. Biomarker Research. 2019;7:19. https://doi.org/10.1186/s40364-019-0170-2.

¹Department of Oncology, The first Affiliated Hospital of Zhengzhou University, Zhengzhou, China





^{*} Correspondence: songyongping@163.com; DELONG_LIU@NYMC.EDU